1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Pipeline Review, H2 2014

Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Pipeline Review, H2 2014’, provides an overview of the Vancomycin Resistant Staphylococcus Aureus Infection (VRSA)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vancomycin Resistant Staphylococcus Aureus Infection (VRSA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vancomycin Resistant Staphylococcus Aureus Infection (VRSA)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vancomycin Resistant Staphylococcus Aureus Infection (VRSA)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Pipeline Review, H2 2014
Table of Contents

Introduction 6
Global Markets Direct Report Coverage 6
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) Overview 7
Therapeutics Development 8
Pipeline Products for Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Overview 8
Pipeline Products for Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Comparative Analysis 9
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Therapeutics under Development by Companies 10
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Therapeutics under Investigation by Universities/Institutes 11
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Products under Development by Companies 14
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Products under Investigation by Universities/Institutes 15
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Companies Involved in Therapeutics Development 16
ContraFect Corporation 16
CrystalGenomics, Inc. 17
Debiopharm International S.A. 18
iNtRON Biotechnology Inc. 19
Wockhardt Limited 20
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
CF-301 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
CG-400549 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Debio-1450 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Epidermicin-NI01 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
S-0111340 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
S-0111342 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
S-0111527 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
SAL-200 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Small Molecules to Activate Perforin-2 Synthesis for Bacterial Infections - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
SP-2078 - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
WCK-4086 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Recent Pipeline Updates 43
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Dormant Projects 46
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Discontinued Products 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Tables

Number of Products under Development for Vancomycin Resistant Staphylococcus Aureus Infection (VRSA), H2 2014 8
Number of Products under Development for Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Pipeline by ContraFect Corporation, H2 2014 16
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Pipeline by CrystalGenomics, Inc., H2 2014 17
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Pipeline by Debiopharm International S.A., H2 2014 18
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Pipeline by iNtRON Biotechnology Inc., H2 2014 19
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Pipeline by Wockhardt Limited, H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 29
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) Therapeutics - Recent Pipeline Updates, H2 2014 43
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Dormant Projects, H2 2014 46
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Discontinued Products, H2 2014 47

List of Figures

Number of Products under Development for Vancomycin Resistant Staphylococcus Aureus Infection (VRSA), H2 2014 8
Number of Products under Development for Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Products, H2 2014 13
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Top 10 Targets, H2 2014 22
Number of Products by Stage and Top 10 Targets, H2 2014 23
Number of Products by Top 10 Mechanism of Actions, H2 2014 24
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 25
Number of Products by Top 10 Routes of Administration, H2 2014 26
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 27
Number of Products by Top 10 Molecule Types, H2 2014 28
Number of Products by Stage and Top 10 Molecule Types, H2 2014 29

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Benzyl Alcohol Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Benzyl Alcohol Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • August 2016
  • by Transparency Market Research

Benzyl alcohol is an aromatic alcohol, which is metabolized into benzoic acid inthe human body. Benzyl alcohol is manufactured by hydrolysis of benzyl chloride in the presence of soda ash through the toluene ...

Asia-Pacific Animal Health Market - Forecast to 2021

Asia-Pacific Animal Health Market - Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The APAC animal health market is estimated to grow at a CAGR of 5.7% during the forecast period, to reach USD 20.25 billion by 2021 from USD 15.32 billion in 2016. Growth in this market can primarily be ...

Silver Sulfadiazine Market: By Application (Wound Care, Burn Care, Skin Care, UTIs) & By Geography -Forecast (2016-2021)

Silver Sulfadiazine Market: By Application (Wound Care, Burn Care, Skin Care, UTIs) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Silver sulfadiazine is an antibacterial drug used for making personal care products. Silver sulfadiazine is listed as the essential medicines by World Health Organization and is widely used as an antibiotic ...

Global Feed Antibiotics Market

October 2016 $ 4250

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in Tanzania

  • December 2016
    9 pages
  • Anti-Infective  

  • Tanzania  

    Africa  

View report >

Anti-Infective Market in Ghana

  • December 2016
    10 pages
  • Anti-Infective  

  • Ghana  

View report >

Anti-Infective and Therapy Market in the US - Forecast

  • December 2016
    249 pages
  • Anti-Infective  

    Therapy  

    Hormone  

  • United States  

View report >

Related Market Segments :

Anti-Infective
Pharmaceutical

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.